Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PXS-5505 |
Synonyms | |
Therapy Description |
PXS-5505 inhibits lysyl oxidases, potentially leading to reduced tumor growth (HPB (2021) 23: S493-S494). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PXS-5505 | PXS 5505|PXS5505 | PXS-5505 inhibits lysyl oxidases, potentially leading to reduced tumor growth (HPB (2021) 23: S493-S494). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04676529 | Phase Ib/II | PXS-5505 | Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis | Active, not recruiting | USA | AUS | 2 |